- Drug Pipelines
- January 2024
- 60 Pages
Global
From €1451EUR$1,500USD£1,243GBP
- Clinical Trials
- April 2024
- 75 Pages
Global
From €1451EUR$1,500USD£1,243GBP
- Report
- March 2024
- 30 Pages
Global
From €3143EUR$3,250USD£2,694GBP
- Report
- January 2024
- 142 Pages
Global
From €4594EUR$4,750USD£3,937GBP
- Report
- January 2024
- 180 Pages
Global
From €7253EUR$7,500USD£6,216GBP
- Report
- October 2023
- 178 Pages
Global
From €4739EUR$4,900USD£4,061GBP
- Report
- October 2023
- 83 Pages
United States
From €3385EUR$3,500USD£2,901GBP
- Report
- March 2021
- 75 Pages
Global
€21275EUR$22,000USD£18,234GBP
- Report
- May 2019
- 84 Pages
Global
From €6765EUR$6,995USD£5,797GBP
- Drug Pipelines
- June 2020
- 150 Pages
Global
From €3385EUR$3,500USD£2,901GBP
- Drug Pipelines
- June 2020
- 92 Pages
Global
From €1934EUR$2,000USD£1,658GBP
- Report
- March 2024
- 101 Pages
Global
From €3500EUR$3,877USD£3,105GBP
- Report
- November 2022
- 159 Pages
Global
From €3385EUR$3,500USD£2,901GBP
Alpha Synuclein is a protein found in the brain and other parts of the nervous system. It is involved in the regulation of neurotransmitter release and is believed to play a role in the development of Parkinson's disease. As such, it has become an important target for drug development in the Central Nervous System (CNS) drugs market.
Alpha Synuclein-targeting drugs are being developed to treat Parkinson's disease, as well as other neurological disorders such as dementia and multiple system atrophy. These drugs are designed to reduce the amount of Alpha Synuclein in the brain, which is believed to be a major contributor to the progression of these diseases.
In addition to drug development, research is also being conducted into the role of Alpha Synuclein in other neurological disorders, such as Alzheimer's disease and amyotrophic lateral sclerosis. This research is aimed at understanding the role of Alpha Synuclein in the development of these diseases, and developing treatments that target the protein.
Companies in the Alpha Synuclein market include AbbVie, Biogen, Merck, Novartis, and Pfizer. Show Less Read more